The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
The RNS can only help things. I think the market at the moment is waiting to see if we can replace our Covid revenue from the States. If we can, or at least make a good stab at it, then all will be well because the Stateside revenue can only increase. Obviously other regions are important but I think it rests on the USA.
I do think it's as simple as that. Both the CMD and the trading update were pretty positive I'm confident we are about to crack breakeven and profitability quite easily by March '24 - maybe even in 1st half of '23 - '24. I'll say one thing - we never had this visibility with Vialogy!!!
Nipt is one thing, but it's the inroads into oncology that will make the big difference imo.
Typo
Bit of news
Daveand
Good and positive, but still all promise and nothing much will happen until some material DRLIVERY starts. Our BOD have form for delays and missed expectations. No insti buying since that we know of and post CMD we did our usual retrace. One material bright but if news since has been LR purchase.
Twix, what did you make of the CMD presentation?
I see a few selling for their £50 profit.. lol
As we have seen time and again and much to Stalker Nutdans pain, I've usually been right here.
Oh dear!
The (clear) point I'm making is to temper all the usual bed wetting euphoria. Pointing out this news is standard type feed for spike and retrace, so a clear message for anyone with open eyes and no agenda to bash. Also, I really hope I'm wrong.
It's got boring though watching all the posters wetting themselves, share price retracing and the Nutjob attacking. Now there's an easy incentive analysis lol
“ quite possible to wobble again on todays delivery. Or not”
-with market inceptive analysis of this precision, why should we worry? Nothing like sitting on the fence, heh?
You guys are alwaysgreat wetting yourselves. No reason today shouldn't be like every other news day. It's not enough to mark it as different enough to burst out of our usual pattern imv. Still, it's good to see lessons simply aren't learnt.
Sorry, but that's my view. I await news that will change our pattern of spike and retrace. Hope I'm wrong btw
Shot up late yesterday. More good news but not any different from usual type, so quite possible to wobble again on todays delivery. Or not, but wouldn't surprise me at all.
Not to mention Ranger benefits in the oncology sector,which is Massive!
The neo-natal technology is why I invested in YGEN pre-Covid. They have such a fantastic offering that it is tough to see it not being adopted more widely in the long-run.
This is only RNS Reach, but still great to see progress being made.
Great news and the fact it makes us only one a few providers in this space who use microdeletions in the workflow bodes well when you consider how much the space is projected to grow.
' personalised healthcare' is definitely the future. TV ads on all the time about it. I wonder if they will get in deeper with MHC as that's what they are doing now, with tests for a number of healthcare issues coming to market very soon.
Great news - I think, just like a boulder tipping over an edge, the YGEN story will gather more and more momentum over 2022 and will be unrecognisable by Christmas.
The market will realise that there is so much more to the company than the old Covid distraction and Ranger will be transformational. GLA
Leaky indeed! Great news though, another good bit if solid foundation. Physicians are asking for more details, so right on cue with this. Will open many more doors I expect. Just wait until the juicy news starts coming in.
Well done!
Haven’t a Scooby’s on the technicals, but I do like
“ provides an expanded offering enabling a more competitive NIPT solution for our global laboratory customers.”,
as well as “ allows the Company to collaborate with new laboratory partners or existing customers”,
not to mention “ broadening the Company's offering.”
Oh, and not forgetting “ with a focus on 'Collaboration to Perform' reflecting our focus on personalised healthcare."
If that’s not a clear indication of the future direction of travel of this company, I don’t know what is.
Not surprised the SP shot up late trading yesterday on (perhaps) leaky news.